The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study
Open accessAbstract
BACKGROUND: It is unknown if extremely early initiation of antiretroviral therapy (ART) may lead to long-term ART-free HIV remission or cure. As a result, we studied 2 individuals recruited from a pre-exposure prophylaxis (PrEP) program who started prophylactic ART an estimated 10 days (Participant A; 54-year-old male) and 12 days (Participant B; 31-year-old male) after infection with peak plasma HIV RNA of 220 copies/mL and 3,343 copies/mL, respectively. Extensive testing of blood and tissue for HIV persistence was performed, and PrEP Participant A underwent analytical treatment interruption (ATI) following 32 weeks of continuous ART. METHODS AND FINDINGS: Colorectal and lymph node tissues, bone marrow, cerebral spinal fluid (CSF), plasma, and very large numbers of peripheral blood mononuclear cells (PBMCs) were obtained longitudinally from both participants and were studied for HIV persistence in several laboratories using molecular and culture-based detection methods, including a murine viral outgrowth assay (mVOA). Both participants initiated PrEP with tenofovir/emtricitabine during very early Fiebig stage I (detectable plasma HIV-1 RNA, antibody negative) followed by 4-drug ART intensification. Following peak viral loads, both participants experienced full suppression of HIV-1 plasma viremia. Over the following 2 years, no further HIV could be detected in blood or tissue from PrEP Participant A despite extensive sampling from ileum, rectum, lymph nodes, bone marrow, CSF, circulating CD4+ T cell subsets, and plasma. No HIV was detected from tissues obtained from PrEP Participant B, but low-level HIV RNA or DNA was intermittently detected from various CD4+ T cell subsets. Over 500 million CD4+ T cells were assayed from both participants in a humanized mouse outgrowth assay. Three of 8 mice infused with CD4+ T cells from PrEP Participant B developed viremia (50 million input cells/surviving mouse), but only 1 of 10 mice infused with CD4+ T cells from PrEP Participant A (53 million input cells/mouse) experienced very low level viremia (201 copies/mL); sequence confirmation was unsuccessful. PrEP Participant A stopped ART and remained aviremic for 7.4 months, rebounding with HIV RNA of 36 copies/mL that rose to 59,805 copies/mL 6 days later. ART was restarted promptly. Rebound plasma HIV sequences were identical to those obtained during acute infection by single-genome sequencing. Mathematical modeling predicted that the latent reservoir size was approximately 200 cells prior to ATI and that only around 1% of individuals with a similar HIV burden may achieve lifelong ART-free remission. Furthermore, we observed that lymphocytes expressing the tumor marker CD30 increased in frequency weeks to months prior to detectable HIV-1 RNA in plasma. This study was limited by the small sample size, which was a result of the rarity of individuals presenting during hyperacute infection. CONCLUSIONS: We report HIV relapse despite initiation of ART at one of the earliest stages of acute HIV infection possible. Near complete or complete loss of detectable HIV in blood and tissues did not lead to indefinite ART-free HIV remission. However, the small numbers of latently infected cells in individuals treated during hyperacute infection may be associated with prolonged ART-free remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Revised Estimates for the Number of Human and Bacteria Cells in the Body
Sender, R., Fuchs, S., & Milo, R. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002533 · Cited by 5,425
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703
Self-citationDefective proviruses rapidly accumulate during acute HIV-1 infection
Bruner, K. M., Murray, A. J., Pollack, R. A., Soliman, M. G., Laskey, S. B., Capoferri, A. A., Lai, J., Strain, M. C., Lada, S. M., Hoh, R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4156 · Cited by 737
Self-citationLiu, A. Y., Cohen, S. E., Vittinghoff, E., Anderson, P. L., Doblecki-Lewis, S., Bacon, O., Chege, W., Postle, B. S., Matheson, T., Amico, K. R., et al. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4683 · Cited by 602 · cited 1×
“The PrEP Demo Project was a prospective study of PrEP for men who have sex with men (MSM) in which participants were tested for HIV both by HIV antibody/antigen combination assay and by HIV RNA on the day of PrEP initiation [18].”
Method
Cited by
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies
Cohn, L. B., Chomont, N., & Deeks, S. G. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.014 · Cited by 284
Self-citationAbrahams, M.-R., Joseph, S. B., Garrett, N., Tyers, L., Moeser, M., Archin, N., Council, O. D., Matten, D., Zhou, S., Doolabh, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw5589 · Cited by 196
De Scheerder, M.-A., Vrancken, B., Dellicour, S., Schlub, T., Lee, E., Shao, W., Rutsaert, S., Verhofstede, C., Kerre, T., Malfait, T., et al. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.08.003 · Cited by 165
Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir
Ling, L., Kim, M., Soper, A., Kovarova, M., Spagnuolo, R. A., Begum, N., Kirchherr, J., Archin, N., Battaglia, D., Cleveland, D., et al. (2024) · mBio · doi:10.1128/mbio.01632-24 · Cited by 14
Target product profile for cell-based and gene-based therapies to achieve a cure for HIV
Lewin, S. R., Bansbach, C., Kemps, D., Mathae, L., Das, K. T., McCune, J. M., Deeks, S. G., & Ndung'u, T. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(24)00277-7 · Cited by 9
Self-citation
Metadata
- Authors
- Henrich, T. J., Hatano, H., Bacon, O., Hogan, L. E., Rutishauser, R., Hill, A., Kearney, M. F., Anderson, E. M., Buchbinder, S. P., Cohen, S. E., Abdel-Mohsen, M., Pohlmeyer, C. W., Fromentin, R., Hoh, R., Liu, A. Y., McCune, J. M., Spindler, J., Metcalf-Pate, K., Hobbs, K. S., Thanh, C., Gibson, E. A., Kuritzkes, D. R., Siliciano, R. F., Price, R. W., Richman, D. D., Chomont, N., Siliciano, J. D., Mellors, J. W., Yukl, S. A., Blankson, J. N., Liegler, T., & Deeks, S. G.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-11-07
- Volume
- 14
- Issue
- 11
- Pages
- e1002417
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2767453022
- Cited by
- 216
- References
- 7
- FWCI
- 15.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. https://app.cochat.ai/papers/10.1371/journal.pmed.1002417
- The paper
- Henrich, T. J., Hatano, H., Bacon, O., Hogan, L. E., Rutishauser, R., Hill, A., Kearney, M. F., Anderson, E. M., Buchbinder, S. P., Cohen, S. E., Abdel-Mohsen, M., Pohlmeyer, C. W., Fromentin, R., Hoh, R., Liu, A. Y., McCune, J. M., Spindler, J., Metcalf-Pate, K., Hobbs, K. S., . . . Deeks, S. G. (2017). HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1002417
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.